Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease.

CONCLUSIONS: This is the first report demonstrating ACPAs in OSW of DED patients and their contribution to ocular surface disease. The first-in-human clinical trial suggests that pooled immune globulin-eye drops are a potential new class of biologic therapies for Dry Eye patients. PMID: 31606460 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31606460?dopt=Abstract

Source: The Ocular Surface - October 9, 2019 Category: Opthalmology Authors: Kwon J, Surenkhuu B, Raju I, Atassi N, Mun J, Chen YF, Sarwar MA, Rosenblatt M, Pradeep A, An S, Dhall N, Mun C, Jain S Tags: Ocul Surf Source Type: research